Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment

• Status: Terminated
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This randomised, double-blind, placebo-controlled clinical trial investigates the neuroprotective effect of rasagiline in patients suffering from a retinal detachment affecting central vision. Based on results from a study in mice suffering from retinal degeneration, the investigators hypothesize that rasagiline delays neurodegeneration in the retina and improves visual acuity outcomes after retinal detachment surgery. Rasagiline is a second-generation propargylamine with neuroprotective properties modulating the caspase-dependent pathway of programmed cell death.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Treatments: Rasagiline

Criteria

Inclusion Criteria:

• Rhegmatogenous retinal detachment

• Central vision affected for less than 72 hours

• Pseudophakic

• Age 18 or over

• Not participating in other clinical trials

• Willing to attend follow-up visits

• Written informed consent

Exclusion Criteria

• Phakic

• Narrow angle glaucoma

• Previous intraocular surgery other than cataract operation

• Retinal disease

• Concurrent treatment with MAO inhibitors

• Pregnancy

• Malignant arterial hypertension

• Liver or kidney failure

• Life-threatening or malignant disease